Navigating the Complexities of Access to Specialty Medications with Chelsey Lindner Shields Health Solutions TRANSCRIPT
Release Date: 05/04/2025
Empowered Patient Podcast
Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated...
info_outlineEmpowered Patient Podcast
Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated...
info_outlineEmpowered Patient Podcast
Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to...
info_outlineEmpowered Patient Podcast
Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to...
info_outlineEmpowered Patient Podcast
Shauna Sweeney, Founder of tendercare, aims to assist caregivers with digital tools and expert support to simplify the process of caring for an aging family member. Recognizing the essential role of caregivers in the quality of life of the patient, tendercare provides a user-friendly interface that incorporates data from wearables and remote sensors to identify early warning signs of risks, help coordinate care, and encourage proactive preparation. The Magic Magnet feature allows caregivers and emergency responders to quickly update and share critical health information. Shauna...
info_outlineEmpowered Patient Podcast
Shauna Sweeney, Founder of tendercare, aims to assist caregivers with digital tools and expert support to simplify the process of caring for an aging family member. Recognizing the essential role of caregivers in the quality of life of the patient, tendercare provides a user-friendly interface that incorporates data from wearables and remote sensors to identify early warning signs of risks, help coordinate care, and encourage proactive preparation. The Magic Magnet feature allows caregivers and emergency responders to quickly update and share critical health information. Shauna...
info_outlineEmpowered Patient Podcast
Karen Sussman Horgan is the Co-Founder and CEO of VAL Health, a behavioral economics consulting firm that helps healthcare organizations drive engagement and nudge patients to improve their health and lifestyle choices. Behavioral economics is the science of understanding how patients make irrational choices based on biases, fear, and faulty analysis of outcomes and risk. Nudges can be carrots or sticks, but in healthcare, the focus is on making the right path easier to follow, reducing friction, and introducing positive reinforcements rather than penalties. Karen explains, "We work across...
info_outlineEmpowered Patient Podcast
Karen Sussman Horgan is the Co-Founder and CEO of VAL Health, a behavioral economics consulting firm that helps healthcare organizations drive engagement and nudge patients to improve their health and lifestyle choices. Behavioral economics is the science of understanding how patients make irrational choices based on biases, fear, and faulty analysis of outcomes and risk. Nudges can be carrots or sticks, but in healthcare, the focus is on making the right path easier to follow, reducing friction, and introducing positive reinforcements rather than penalties. Karen explains, "We work across...
info_outlineEmpowered Patient Podcast
Christine Lee, Head of Health Strategy and Partnerships at AnalyticsIQ, focuses on helping healthcare brands and pharmaceutical companies better understand and engage with healthcare providers by taking into account data beyond their professional lives. This data-driven Provider as a Person approach analyzes the healthcare professional's personal characteristics, outside interests, decision-making style, and preferred method of communication. The goal is to foster more meaningful relationships with providers, address provider burnout, and improve patient outcomes. Christine explains,...
info_outlineEmpowered Patient Podcast
Christine Lee, Head of Health Strategy and Partnerships at AnalyticsIQ, focuses on helping healthcare brands and pharmaceutical companies better understand and engage with healthcare providers by taking into account data beyond their professional lives. This data-driven Provider as a Person approach analyzes the healthcare professional's personal characteristics, outside interests, decision-making style, and preferred method of communication. The goal is to foster more meaningful relationships with providers, address provider burnout, and improve patient outcomes. Christine explains,...
info_outlineChelsey Lindner, a pharmacist and Manager of Clinical Services at Shields Health Solutions, provides insights about the growing prevalence of oral and subcutaneous injection oncology medications, which is shifting the delivery of care from the clinic to at-home. This innovation in cancer care introduces complexities around accessing and affording these specialty drugs and requires the skills of a specialty pharmacy to support the patients and providers. In an integrated care model, there is also a growing need for attention to medication adherence and monitoring for side effects by these pharmacists.
Chelsey explains, "Shields is considered a specialty pharmacy integrator. We partner with health systems across the country to help them operate best-in-class specialty pharmacy programs. We are focused on improving patient outcomes through specialized pharmacy services and supporting the optimized use of specialty medications through navigation of access, care coordination, and comprehensive medication management. So those are three of the big services Shields offers as a company."
"I would say that the number one component that these oral oncology medications offer is a level of patient convenience and maintenance of their quality of life. Because what was a cancer diagnosis 20 years ago meant they were going to have to come to the health center or be admitted to the hospital to receive their treatment. Whereas now, when a patient might be faced with a certain cancer diagnosis, they will be managing it like a chronic condition. They can stay at home, they can stay with their families. They can do all of those things that they want to do that help support that quality of life as they're going through active cancer treatment. And so with that certainly comes, I think, a level of popularity. And I think the pharmaceutical companies certainly would be incentivized to continue the research in this area and the development of these agents."
#ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #CancerTreatment #MedicationAdherence